



Corporate Presentation, Oct 2016

ASX: NOX

In a nutshell.....

In 1971, cancer researchers dreamt of turning cancer into a manageable, non-lethal, chronic disease

45 years later that dream remains elusive for most types of cancer

In 1971, chemotherapy and radiotherapy were the standard frontline therapies

45 years later, chemotherapy and radiotherapy remain our best treatment options

In a nutshell.....

The dream remains elusive because chemotherapy and radiotherapy are not being used to their full powers

***because* damage to healthy cells dictates the highest dose of chemo and radiotherapy that can be used, and that dose is not enough to kill all cancer cells**

If a way could be found to increase the sensitivity of cancer cells to current doses of chemotherapy and radiotherapy so that ALL cancer cells were killed

..... then the 1971 dream should be achieved.

Noxopharm believes it has the answer.....

IDRONOXIL: sensitises cancer cells (and only cancer cells) to standard chemotherapy and radiotherapy

IDRONOXIL : dramatic level of sensitisation >2000x

NOX66: delivering IDRONOXIL in a form designed to maintain its activity in the body

NOX66: Noxopharm seeks to make NOX66 standard of care for all patients undergoing chemotherapy and radiotherapy



45 years
later




1971:
President Richard Nixon signs
National Cancer Act
Declares “**War on cancer**”

The war
continues

2016:
Vice-President Joe Biden
Announces “**Cancer moonshot**”

After 45 years of 'the war on cancer'

10-year survival rates remain poor for many cancers




Source; Cancer Research UK

Little or no progress made in survival outcome for cancers of:

- Pancreas
- Lung
- Brain
- Head and neck
- Oesophagus
- Stomach
- Cervix
- Bladder

BUT....even where progress has been made, most cancers eventually recur and ultimately become resistant to chemotherapy and radiotherapy

Frontline cancer therapies work by damaging DNA



Radiotherapy

Chemotherapy




Aim is to damage
DNA beyond repair



cell dies

The problem




MAXIMUM TOLERABLE DOSE

Highest dose of chemotherapy or radiotherapy that can be delivered is determined by the highest dose that can be tolerated by the patient.

The problem


The Maximum Tolerated Dose leaves many cancer cells alive



The solution

To sensitise cancer cells
(*and only cancer cells*)
to DNA-damaging effects of
chemotherapy and radiotherapy so
that **ALL** cancer cells are killed

The answer



Idronoxil


Sensitises all forms of cancer cells
(but not healthy cells)

by > 2,000x

to all standard cytotoxic
chemotherapy drugs

and radiotherapy

Idronoxil history



Discovered in 1992

Basis of formation of
Novogen Ltd
(ASX:1994).

Named **phenoxodiol**.
Potent ability to
sensitise chemotherapy
confirmed


Enters clinic in 1999

Novogen market cap =
\$900 million


Evidence of anti-cancer
benefits observed in
Phase II studies alone
and in combination

Phase III study
(phenoxodiol +
carboplatin) in late-
stage ovarian cancer
abandoned in 2009

For personal use only




Body attaches sugar to allow drug to be excreted in urine




Drug rendered **INACTIVE**

The solution: NOX66



Body prevented from attaching sugar



Drug remains in **ACTIVE** form

Clinical Program



Cytotoxic chemotherapy

Radiotherapy

Clinical strategy

To run a broad clinical trials program designed to identify:

1. The best treatment combination

- chemotherapy
- radiotherapy

2. The best purpose of use


- Make standard doses work better
- Allow use of lower doses

3. Optimal cancer type


- Prostate, breast, lung, sarcoma

And to have that decision by end-2017


Chemotherapy Study



Radiotherapy Study 1



Radiotherapy Study 2



Cancer metrics

Annual spend on anti-cancer drugs = >US\$100 billion



Top 10 anti-cancer drugs = US\$45 billion



What value a drug that would have a rationale for use in most patients?

Our objective

To bring to market the first drug that sensitises cancer cells to cancer therapies



to improve the survival outcomes of standard **chemotherapy** and **radiotherapy**



and allow effective dosages of standard chemotherapy and radiotherapy
to be lowered to non-toxic levels



and thereby provide treatment options for the elderly and frail and the significant
population of patients who elect **not to undergo toxic therapies**

Clinical studies


Patients with late-stage cancers that have failed to respond to **standard therapies** and have **no remaining standard treatment options**

Q1. Can NOX66 result in a significant anti-cancer response where none is expected?


Q2. Can NOX66 allow dosages of chemotherapy and radiotherapy to be lowered to levels that will be well tolerated?

Indicative timelines


Chemotherapy Study



Radiotherapy Study 1



Radiotherapy Study 2



IP position

Idronoxil

Structure not patentable. First described by G. Kelly in 1994.

Patent lodgement

Family of provisional patents lodged. Claims revolve around innovative formulation designed to block Phase 2 metabolism and conserve bio-activity

2nd and 3rd generation products

R&D programs initiated with intention of delivering a family of therapeutics with specific abilities to cancel resistance mechanisms

Experienced team



Graham Kelly *PhD*
Managing Director

- Head of research team at University of Sydney that discovered idronoxil in 1992
- Founded (CEO) Novogen Ltd (ASX 1994; NASDAQ 1998). Executive Director 1994-2006
- Chairman of Marshall Edwards Inc (AIM 2001; NASDAQ 2003)
- CEO/Executive Chairman Novogen Ltd 2012-2015
- Founded Noxopharm October 2015



Dr Ian Dixon *PhD, MBA*
Non-Executive Director

- Over 20 years' experience in the biotechnology and medical device industries and was founder/co-founder of numerous successful technology companies, including Cynata Ltd, Genscreen Pty Ltd and August Therapeutics.
- Previously a non-executive Director of Cell Therapies Pty Ltd, and Director of the Product Group at Invetech, now part of Danaher Corporation (NYSE: DHR).
- Led early development of the anti-tropomyosin drug technology that his company licensed to Novogen Ltd.



Peter Marks
Non-Executive Chairman

- 30+ years experience in corporate finance, specializing in capital raisings (for listed and unlisted companies), underwriting, IPOs and venture capital transactions.
- Participated in over \$2B in public and private capital raised.
- Executive and Non-Executive Director of a number of listed entities on the ASX and AIM



Phillip Hains *MBA*
Company Secretary

- Phillip holds a Masters of Business Administration from RMIT and a Public Practice Certificate from the Institute of Chartered Accountants.
- As a chartered accountant, Phillip operates his own specialist public practice, The CFO Solution, providing back-office support, financial reporting and compliance systems for public companies.
- Phillip has over 20 years' experience in providing businesses with accounting, administration, compliance and general management services.

Key metrics

Shares outstanding

75M

30M free; 45M escrowed (July 2019)

Other

22.5M options (\$0.30) (2021)

10M performance shares (\$50M market cap) (2021)

Cash position

\$6M IPO (9 Aug 2016)

\$5M (Sept 2016)

Budgeted to take Company to proof-of-concept stage

Value drivers

Large
market size

Substantial
unmet need for
most patients
with solid
cancers

Lack of
competition

No current drug
or known drug
in development
with same
ability to
reverse cancer
resistance
mechanisms

Experience

Over 20 years'
experience with
this technology
generally and
this drug
specifically

Clinic-
ready

Phase 1 study
to commence in
4Q16

Expeditious
clinical plan

Indication of
efficacy
designed to be
available within
12-15 months

Key Messages



- Resistance to chemotherapy/radiotherapy remains the most pressing and largest problem facing patients
- No drug has come to market that successfully treats this problem
- WE EXPECT TO KNOW WITHIN 12 MONTHS OF THE SUCCESS OF OUR MISSION IN RADIOOTHERAPY
- WE EXPECT TO KNOW WITHIN 12 MONTHS OF THE SUCCESS OF OUR MISSION IN CHEMOTHERAPY
- A SUCCESSFUL OUTCOME IS A MAJOR SHARE OF THE \$100 BILLION ONCOLOGY DRUG MARKET

✓ Lean, focused operation

✓ 5 key inflection points anticipated within next 18 months

✓ Potential for NOX66 to become standard of care

Disclaimer



- ▶ *This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or invitation to subscribe for or purchase any shares in NOX. No agreement to subscribe for securities in the NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.*
- ▶ *This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.*
- ▶ *This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.*
- ▶ *Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.*
- ▶ *Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.*

Contact



Dr Graham Kelly
Chief Executive Officer

graham.kelly@noxopharm.com